Mizuho lowered the firm’s price target on ResMed (RMD) to $250 from $265 and keeps an Outperform rating on the shares. The company reported in-line fiscal Q3 results and sees little to no tariff impact, the analyst tells investors in a research note. The firm says ResMed is “on right side of tariff equation” and there is no evidence of GLP-1 cannibalization.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- ResMed price target lowered to $248 from $260 at Piper Sandler
- ResMed price target raised to $255 from $247 at RBC Capital
- ResMed: Strong Financial Performance and Strategic Positioning Justify Buy Rating
- ResMed price target raised to $274 from $269 at KeyBanc
- Resmed’s Strong Q3 Performance and Strategic Positioning Justify Buy Rating